Susquehanna International Group, LLP Aadi Bioscience, Inc. Call Options Transaction History

Susquehanna International Group, LLP

4 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q4 2022 Feb 14, 2023	SELL	$11.99 - $14.5 $483,197 - $584,350	-40,300 Reduced 56.28%	31,300 $401,000
Q3 2022 Nov 14, 2022	SELL	$12.03 - $14.22 $92,631 - $109,494	-7,700 Reduced 9.71%	71,600 $1.01 Million
Q2 2022 Aug 15, 2022	BUY	$11.57 - $17.92 $290,407 - $449,792	25,100 Added 46.31%	79,300 $977,000
Q1 2022 May 16, 2022	BUY	$16.65 - $24.97 $902,429 - $1.35 Million	54,200 New	54,200 $920,000

12M

9.4K

2.5K

Ticker AADI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 21,016,800
Market Cap $40.6M
Description
Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, ...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.